This content was updated in October 2020 and will be valid for one year.
ADA/EASD guidelines now recommend GLP-1 RAs as an option in most patient circumstances, as well as the first injectable therapy to be used before advancing to insulin. However, the move from all-oral treatment to an injectable regimen can come with a number of concerns for people with diabetes. How can we help address fears surrounding injections, and work with patients to help them make informed treatment decisions?
Join Professor Steve Bain and Mr Ken Tait for an interactive exploration of a model patient case. View roleplay scenarios that replicate common real-world conversations, and hear insights from both an expert clinician and patient advocate on the thoughts behind both partners in care.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.